These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

In recent years, a growing number of scientific studies have backed an alarming hypothesis: Alzheimer's disease isn't just a ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

Art Still, former Kansas City Chiefs player, was diagnosed with ATTR amyloidosis, a rare heart condition more common in Black men. He shares symptoms.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

A Potential Solution for Neurodegenerative Diseases. Open Access Library Journal, 12, 1-16. doi: 10.4236/oalib.1112714 . Alzheimer’s Disease (AD), a complex neurodegenerative condition, significantly ...

Contrary to popular belief, an early bedtime doesn’t necessarily equal better health. Here’s the best time to pack in that ...

Alzheimer’s Disease (AD) is a major neurodegenerative disorder contributing to 60-70% of dementia cases globally, affecting approximately 50 million ...

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval- ...